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Abstract
We report clinico-pathological features of a 65-year-old woman and a 56-year-
old man with a 5-year clinical history who had clinical and neuropathological
characteristics of upper and lower motor neuron disease consistent with amy-
otrophic lateral sclerosis, and a frontotemporal atrophy pattern in case 2 with-
out TDP-43 pathology. Instead, spongiform change and pathological prion
protein deposits were observed in several brain regions. No prion protein gene
mutations were found. Western blot analysis showed a five-band profile com-
patible with variably protease-sensitive prionopathy. We conclude that this dis-
ease can display prolonged disease duration and clinico-pathological features
within the ALS/FTLD spectrum.
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Introduction
Creutzfeldt–Jakob disease (CJD) is a fatal neurodegenera-
tive disorder caused by a conformational alteration of the
prion-protein (PrPsc). Typical clinical features include
rapidly progressive dementia, cerebellar, extrapyramidal,
pyramidal, and visual signs. In 2008, a novel sporadic
variably protease-sensitive prionopathy (VPSPr) was
described.1 VPSPr differs from classical CJD in its clinical
presentation with prominent aphasia, ataxia, and parkin-
sonian signs; a longer disease duration of up to
45 months; and by a unique ladder-like electrophoretic
profile of proteinase K (PK)-resistant PrPsc fragments.1
Despite the frequent finding of pyramidal signs in CJD,2–4
we are not aware of reports of VPSPr presenting simulta-
neous upper and lower motor neuron (MN) dysfunction,
as in ALS, and as we present here.
Patients and Methods
The first patient was a 65-year-old woman, visited at the
Neurology Department for gait difficulties since 1 year.
Neurological examination disclosed “scissor” gait, spastic-
ity, and hypertonia of lower limbs, brisk reflexes with
patellar and ankle clonus reflexes, and Hoffmann0s and
Babinski signs. She had symmetrical atrophy of the shoul-
der girdle and the thenar eminence. Neither cerebellar
nor sensory alterations were detected. Cervical-brain MRI
revealed slight ventricular enlargement. Dopamine-trans-
porter SPECT was unremarkable. Electromyography con-
firmed the alteration of the pyramidal tract in the four
limbs with denervation signs in the upper limbs and
indemnity of the somatosensory pathway. Neuropsychol-
ogy revealed mild, fronto-subcortical cognitive impair-
ment. Lumbar puncture yielded normal cell count and
routine biochemical parameters. 14-3-3 protein determi-
nation was negative. No mutations of C9orf72 or
TARDBP were detected.
The disease progressed and signs of lower MN were
clearly appreciable in three body regions with weakness and
atrophy of several muscular groups meeting the revised El
Escorial Criteria for definite ALS.5 The patient died in a
long-term care facility at age 70, in a state of complete
anartria, dysphagia requiring feeding by gastrostomy, and
tetraplegia, after a total disease duration of 5 years.
The second patient was a 56-year-old man, visited at
the Neurology Department for cognitive and behavioral
problems since 1 year. His character became more irrita-
ble, with inappropriate comments and childish attitude.
Neurological examination disclosed apraxia, apathy, and
anosognosia and he scored 15/30 on the Minimental
State Examination. No muscular weakness or pyramidal
signs were observed, but fasciculations. Electromyography
showed mild generalized denervation with alteration of
the pyramidal tract and indemnity of the somatosensory
pathway. CSF showed mildly increased total protein con-
centration with no cells, normal Ab42 (891 pg/mL),
increased total tau (1200 pg/mL), and phospho-tau
(95.54 pg/mL). There was no C9orf72 expansion muta-
tion and APOE genotype was e3/3. At follow up, he
developed gait problems and cognitive and motor prob-
lems worsened rapidly, becoming mute and wheel chair
dependent 3 years after disease onset. He required percu-
taneous endoscopic gastrostomy and he died at age 59
due to respiratory complications, 52 months after symp-
toms onset.
Preparation of brain homogenate, PK
digestion, and PrPsc deglycosylation
Fresh frozen brain tissue was homogenized (10% w/v) in
lysis buffer (100 mmol/L NaCl, 10 mmol/L EDTA, 0.5%
Nonidet P-40, 0.5% sodium deoxycholate, 100 mmol/L
Tris) at pH 6.9 and digested with proteinase K (PK)
(Roche Diagnostics) at a final concentration of 2 U/mL
for 1 h at 37°C. After blocking PK activity with phenyl-
methylsulfonyl fluoride (PMSF, final concentration
3.6 mmol/L), samples were boiled in sample buffer (final
concentration: 3% SDS, 4% b-mercaptoethanol, 10%
glycerol, 2 mmol/L EDTA, 62.5 mmol/L Tris) for 6 min
at 100°C. N-Linked glycans were removed by using a pep-
tide-N-glycosidase F kit (New England Biolabs) according
to the manufacturer’s instructions.
Results
Neuropathological findings
The brain of both brain donors was removed for diagnos-
tic and research purposes after obtaining written
informed consent by the next of kin.
Case 1
Unfixed brain weight was 935 g. Gross examination
revealed prominent global atrophy (Fig. 1, upper left)
accentuated at the precentral gyrus, pontine base, bulbar
pyramids, and spinal cord. Histology revealed prominent
loss of MN of the spinal cord, and severe degeneration of
lateral and anterior corticospinal tracts (Fig. 1G1–H1).
There were no Bunina bodies and no other inclusion
bodies. Neuronal loss, gliosis, and spongiform change was
found in the neuropil of all neocortical regions and basal
ganglia (Fig. 1A1). Severe loss of Betz cells and intense
microglial reaction was seen in the primary motor cortex.
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Figure 1. Neuropathological findings. A1–H1: Representative images of patient 1 A2–H2: Representative images of patient 2 Upper panel: Gross
aspect of the right brain hemisphere of each patient shows a frontally accentuated brain atrophy in patient 1 (left) and a more generalized
atrophy pattern in patient 2 (right). A1–B1: Haematoxylin–eosin-stained sections show mild spongiform change in frontal cortex (A1) and
intraneuronal vacuoles in neurons from the basis pontis (B1); cerebellum was well preserved and showed only isolated torpedoes in granular layer,
without obvious spongiform change in molecular layer (not shown). C1–D1: Immunohistochemistry for PrP (antibody 12F10) reveals abnormal
diffuse synaptic PrPsc deposits in grey matter in frontal cortex and, hippocampus with focal atypical deposits in subiculum (D1) and diffuse
patches and occasional “microplaques” in cerebellar molecular layer (not shown). E1–H1: Luxol-fast blue stain (E1, H1) and immunohistochemistry
for neurofilaments (RT97) (G1) showing prominent atrophy of spinal cord with degeneration of lateral and anterior corticospinal tracts (E1), with
loss of axonal profiles (G1: upper panel shows reduced density of axonal profiles, in comparison with lower panel, which shows normal density)
and myelin sheaths (H1: upper panel shows reduced density of myelin sheaths in comparison with lower panel, which shows normal density)
associated with intense macrophage activity (not shown). Haematoxylin–eosin staining reveals loss of motor neurons in anterior horns, with
shrunken residual neurons (F1). A2–B2: H&E-stained section of the frontal cortex reveals a characteristic superficial spongiosis as seen in FTLD.
Superficial cortical layers show perineuronal, irregular vacuoles (B2 upper panel), while deeper cortical layers show mild spongiform change (B2
lower panel). C2–F2: Immunohistochemistry for PrP (antibody 12F10) reveals intense diffuse synaptic deposits with some fleecy areas in CA1
sector of the hippocampus (C2, D2), and diffuse, patchy and microplaques in molecular layer of the cerebellum (E2, F2). Occasional intraneuronal
granular and coarser immunoreactivity was observed in cortical neurons (F2, inset). G2–H2: Signs of corticospinal tract degeneration at the level
of thoracic spinal cord with prominent microglial activation in grey matter and macrophage activity in degenerated tracts (H2, anti-HLA-DR).
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Neuronal loss was also observed in the pontine nuclei,
with discrete spongiform change and intraneuronal vac-
uoles (Fig. 1B1). Immunohistochemistry (anti-PrP 12F10,
Bertin Pharma, France) after appropriate tissue pretreat-
ment showed scarce synaptic PrPsc deposits in cortical
areas (Fig. 1C), basal ganglia, thalamus, pons, and spinal
cord. Atypical patchy PrPsc aggregates and pseudoplaques
were identified in the hippocampus, primary visual area
(Fig. 1D1), and cerebellum. Isolated tau+ (AT8, Thermo-
Scientific, Rockford, IL) neurofibrillary pathology was
identified in the entorhinal cortex and occasional alpha-
synuclein (KM51, Novocastra, Newcastle, UK) aggregates
in the olfactory bulb. No additional abnormal protein
aggregates (beta-amyloid (6F/3D, DAKO, Glostrup, Den-
mark), TDP-43 (Abnova, Taiwan), FUS (Sigma Aldrich,
St. Louis, MO, USA; or Lifespan Biosciences, Seattle,
WA), ubiquitin (DAKO), or p-62 (Transduction Labora-
tories TM)) were identified.
Case 2
Unfixed brain weight was 1015 g. Gross examination
revealed prominent global atrophy, preferentially involv-
ing frontal, temporal and parietal regions (Fig. 1, upper
right), and caudate nuclei. Histology revealed moderate
neuronal loss and gliosis in cortical areas, basal ganglia,
and anterior horn of the spinal cord at all levels, with sev-
ere degeneration of lateral and anterior corticospinal
tracts (Fig. 1G2, H2). Besides focal superficial spongiosis
in frontal (Fig. 1A2, B2) and temporal cortex, spongiform
change was evident in cortical areas (Fig. 1B2, lower
panel), limbic system, basal ganglia, and cerebellum. No
abnormal ubiquitin, p62, TDP-43, FUS tau, beta-amyloid,
alpha-synuclein, or alpha-internexin aggregates were
detected. In contrast, diffuse abnormal PrPsc deposits
(12F10 antibody) were detected in all gray matter regions,
combining a diffuse synaptic pattern with focal fleecy
aspect (Fig. 1E2, F2), some intraneuronal deposits
(Fig. 1F2, inset), and frequent patches and microplaque-
like deposits in cerebellum (Fig. 1C2–D2).
Molecular studies
Western blot analysis of striatum and temporal cortex (3F4
anti-PrP antibody) revealed in both patients a pattern of
five relatively weak bands migrating at 25, 22, 19, 17, and
8 kDa (Fig. 2). Deglycosylation, although not fully com-
plete especially in one sample (lane 5), showed an enrich-
ment or the lack of modification of the 19, 17, and 8 kDa
bands, representing unglycosylated PrPSc fragments.
Analysis of PRNP revealed methionine homozygosity at
codon 129 in case 1 and valine homozygosity in case 2,
without mutations or insertions.
RT-QuIC analysis of CSF of patient 2 (obtained
10 days after the initial visit) was performed retrospec-
tively (as described previously6) after obtaining the neu-
ropathological result and was negative.
Discussion
We present two patients with neuropathologically and
biochemically confirmed VPSPr manifesting symptoms
within the ALS/FTD clinical spectrum. The patient who
presented primary with ALS carried MM at PRNP codon
129 while the patient with FTD-ALS was VV. In VPSPr,
the most frequent genotype is VV (65%) and 60% of
patients may have symptoms mimicking FTD.1 In con-
trast, among less frequent genotypes, MV (23%) and MM
(12%), motor signs are more common.
Upper MN signs are a common and prominent finding
in CJD and have been included in clinical criteria.7
Although the term “amyotrophic form of CJD” has been
used in the past for CJD patients in whom amyotrophy
was a prominent feature8,9 this entity has been questioned
as amyotrophy may be common at end stages of disease.9
Only few sCJD patients with amyotrophy as an early and
prominent feature, with short disease duration (1–8
months)2–4 have been reported.
Recently, a patient with concomitant VPSPr and ALS-
TDP43 has been reported.10 This was a woman with a
4-year history of progressive dementia and features sug-
gestive of Lewy body disease. Neuropathology showed a
spongiform encephalopathy, a five-band ladder profile of
abnormal PrP consistent with VPSPr, and TDP-43 neu-
ronal inclusions in motor neurons.
Recently, Yaguchi et al. also reported a CJD patient
with clinical features of ALS/FTD, but prion diagnosis
relied on RT-QuiC, but not on postmortem examina-
tion.11
Two clinical features differentiate our patients from
most previous CJD cases: the simultaneous development
of upper and lower MN dysfunction, fulfilling the revised
El Escorial Criteria for definite ALS,5 and the atypically
prolonged disease duration. Neuropathological findings
were consistent with ALS in case 1. However, and in con-
trast to the case reported by Cannon et al.10 we did not
find ubiquitin-, neurofilament, TDP43-, or FUS-positive
neuronal inclusions or Bunina bodies. Instead, we found
spongiform change and PrPSc deposition widely dis-
tributed throughout the brain and spinal cord, which
together with absent PRNP mutations, the western blot
pattern and the atypical immunohistochemical features
are consistent with VPSPr. The same neuropathological
features were observed in patient 2, who had additional
FTLD. We could not find an alternative explanation for
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this clinico-pathological phenotype. The possibility of the
co-occurrence of two rare conditions, VPSPr and an atyp-
ical form of ALS/FTLD lacking abnormal protein inclu-
sions seems unlikely. The MM genotype of our first
patient with ALS, which is the less frequent genotype in
VPSPr, could be another explanation for the atypical clin-
ical course, while valine homozygosity of the second
patient could be more concordant with dementia and
psychiatric symptoms.
In conclusion, we describe ALS/FTD-ALS mimics with
underlying VPSPr, that expands the phenotypic spectrum
of human prion disease, specifically of VPSPr.
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